Q32 Bio Inc.(QTTB)是一家开创性的生物技术公司,专注于开发先进的抗体疗法,用于自身免疫性疾病和免疫反应优化。凭借其专有技术平台,公司正在构建强大的治疗候选药物管线,旨在恢复免疫平衡并解决重大未被满足的医疗需求。在经验丰富的管理团队指导下,并通过战略合作得到加强,Q32 Bio处于有利地位,能够通过专注的研发计划为医疗保健做出有影响力的贡献,并为其股东创造可观的长期价值。
财务指标
营业收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$5373.7万
2025-09-30
$0
营业支出
2026-06-30
$903.3万
2026-03-31
$772.2万
2025-12-31
$785.8万
2025-09-30
$757.7万
净利润
2026-06-30
-$894.6万
2026-03-31
-$760.9万
2025-12-31
$5773万
2025-09-30
-$738.9万
净利润率
2026-06-30
--
2026-03-31
--
2025-12-31
107.43%
2025-09-30
--
每股收益
2026-06-30
$-0.44
2026-03-31
$-0.54
2025-12-31
$4.58
2025-09-30
$-0.60
息税折旧摊销前利润
2026-06-30
-$886.1万
2026-03-31
-$763.2万
2025-12-31
$5802万
2025-09-30
-$699.8万
有效税率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$0
$0
$5373.7万
$0
营业支出
$903.3万
$772.2万
$785.8万
$757.7万
净利润
-$894.6万
-$760.9万
$5773万
-$738.9万
净利润率
--
--
107.43%
--
每股收益
$-0.44
$-0.54
$4.58
$-0.60
息税折旧摊销前利润
-$886.1万
-$763.2万
$5802万
-$699.8万
有效税率
--
--
--
--
常见问题
QTTB is the ticker symbol for Q BioMed Inc., a biotechnology company focused on developing and commercializing therapeutics and diagnostic products for underserved medical conditions. The stock represents an ownership stake in the company and trades on U.S. over-the-counter markets. Investors can review the latest QTTB company profile and market data on the stock detail page for current information.
Several factors can influence QTTB's share price, including clinical trial results, regulatory decisions from agencies such as the FDA, product development milestones, financing activities, and changes in the company's financial condition. Broader market sentiment toward small-cap biotechnology stocks and general economic conditions can also play a role. Because QTTB trades over the counter, liquidity and trading volume may amplify price movements relative to larger exchange-listed companies.
QTTB has historically shown significant price volatility, which is common among small-cap biotechnology companies with limited revenue and ongoing development programs. News about trials, regulatory filings, or financing can cause sharp moves. Trading on over-the-counter markets may further amplify swings due to thinner liquidity and wider bid-ask spreads. For current volatility measures such as beta or recent price ranges, refer to the latest data displayed on the QTTB stock page.
QTTB has not historically paid dividends, which is typical for development-stage biotechnology companies that reinvest available capital into research, clinical programs, and operations rather than returning cash to shareholders. Any future decision to initiate a dividend would depend on the company's financial position and strategic priorities. For the most current dividend status, check the dividend section of the QTTB stock detail page.
Key risks for QTTB include the possibility that product candidates fail in clinical development or do not receive regulatory approval, the need for additional capital that could dilute existing shareholders, and limited revenue relative to operating expenses. As an over-the-counter stock, QTTB may also face lower liquidity and less stringent reporting requirements than exchange-listed companies. These factors can contribute to substantial price swings.
Earnings information for QTTB, including quarterly and annual reports, can typically be found through the company's investor relations page, SEC filings such as 10-K and 10-Q reports, and financial data providers. These sources detail revenue, net income or loss, and operating expenses. The QTTB stock detail page may also summarize recent financial results and link to relevant filings for further review.